- $259.69m
- $415.54m
- $243.80m
- 55
- 69
- 79
- 75
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 19 | 57.4 | 138 | 161 | 244 |
Cost of Revenue | |||||
Gross Profit | 3.99 | 12.1 | 29.4 | 28.7 | 58 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 22.2 | 76 | 208 | 307 | 259 |
Operating Profit | -3.22 | -18.6 | -70.2 | -146 | -15.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.35 | -19.8 | -72.8 | -139 | -27.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.36 | -15.7 | -61.5 | -131 | -27.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -3.36 | -15.7 | -61.5 | -131 | -27.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.36 | -15.7 | -61.5 | -132 | -47.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.054 | -0.035 | -0.816 | -0.982 | -0.71 |